

The individual experienced lifelong insensitivity to pain and was oblivious to cuts and burns, did not experience pain during childbirth, did not experience pain from degeneration of a hip that required hip replacement surgery, and did not require analgesics for postoperative pain. Homozygous microdeletion in the FAAH-OUT pseudogene of the fatty acid amide hydrolase chromosomal region that is expressed in the brain and dorsal root ganglia was identified as the cause of congenital analgesia in a single individual (as of 2019). People with homozygous mutations of the PRDM12 gene experience congenital insensitivity to pain (CIP). PRDM12 gene is normally switched on during the development of pain-sensing nerve cells. As these channels are likely involved in the formation and propagation of action potentials in such neurons, it is expected that a loss of function mutation in SCN9A leads to abolished nociceptive pain propagation. Na v1.7 channels are expressed at high levels in nociceptive neurons of the dorsal root ganglia. This results in a truncated non-functional protein.

There are three mutations in SCN9A: W897X, located in the P-loop of domain 2 I767X, located in the S2 segment of domain 2 and S459X, located in the linker region between domains 1 and 2. Patients with such mutations are congenitally insensitive to pain and lack other neuropathies. In all cases, this disorder can be in the voltage-gated sodium channel SCN9A ( Na v1.7).

In this case, naloxone may be a treatment, but it does not always work. It may be that the condition is caused by increased production of endorphins in the brain.
